The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review
Authors:
Open Access
- 1 January 2022
- journal article
- review article
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 27
Abstract
Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the treatment of HF. At present, there have been few systematic and detailed reviews discussing the efficacy and safety of sacubitril/valsartan in HF. In this review, we first introduced the pharmacological mechanisms of sacubitril/valsartan, including the reduction in the degradation of natriuretic peptides in the natriuretic peptide system and inhibition of the renin-angiotensin system. Then, we summarized the efficacy of sacubitril/valsartan in HF patients with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF) including the reduction in risks of mortality and hospitalization, reversal of cardiac remodeling, regulation of biomarkers of HF, improvement of the quality of life, antiarrhythmia, improving renal dysfunction and regulation of metabolism. Finally, we discussed the safety and tolerability of sacubitril/valsartan in the treatment of HFrEF or HFpEF. Compared with ACEIs/ARBs or placebo, sacubitril/valsartan showed good safety and tolerability, although the risk of hypotension might be high. In conclusion, the overwhelming majority of studies show that sacubitril/valsartan is effective and safe in the treatment of HFrEF patients but that it has little benefit in HFpEF patients. Sacubitril/valsartan will probably be a promising anti-HF drug in the near future.Keywords
Funding Information
- Natural Science Foundation of Shandong Province (ZR2020QH005)
This publication has 67 references indexed in Scilit:
- The Renin-Angiotensin-Aldosterone System and Heart FailureCardiology Clinics, 2014
- 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive SummaryCirculation, 2013
- Assessing health-related quality of life in patients with heart failure: a systematic, standardized comparison of available measuresHeart Failure Reviews, 2013
- The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trialThe Lancet, 2012
- Comparative Value of NYHA Functional Class and Quality-of-Life Questionnaire Scores in Assessing Heart FailureJournal of Cardiopulmonary Rehabilitation and Prevention, 2010
- Natriuretic Peptides: Their Structures, Receptors, Physiologic Functions and Therapeutic Applications2009
- Natriuretic PeptidesHeart Disease, 2003
- Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart FailureCirculation, 2002
- Measurement of the QT interval and the risk associated with QTc interval prolongation: A reviewThe American Journal of Cardiology, 1993
- Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers.Circulation Research, 1992